PALO ALTO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) and its affiliate company Venthera, Inc. (Venthera), today announced preliminary data from the ...
First-in-human Phase 1/2 trial in patients with venous malformations (VMs), lymphatic malformations (LMs), and venolymphatic malformations (VLMs) associated with PIK3CA or TEK mutations PALO ALTO, ...
DelveInsight's “Vascular Malformations Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Vascular Malformations pipeline landscape. It ...
The options for treating vascular malformations in infants and children are limited by the size of the child and the location of the lesion. Surgery is associated with high rates of recurrence, and ...
Lymphatic malformations are uncommon congenital vascular anomalies that can cause complications including obstruction of vital organs and their function, recurrent infection, and disfigurement. 1 ...
PALO ALTO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Venthera, which is focused on developing new treatment options for patients with rare vascular ...
BridgeBio Pharma and Affiliate Venthera, a company focused on developing new treatment options for patients with rare vascular anomalies, announced that the first patient has been dosed in its phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results